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Clinical Issues Associated with Urine Testing of 
Substances of Abuse 
Kimberly D. Eskridge, Pharm.D., and Sally K. Guthrie, Pharm.D. 
Several factors may affect the validity and outcome of urine testing for abused 
drugs such as amphetamines, barbiturates, benzodiazepines, cannabinoids, 
cocaine, ethanol, opiates, and phencyclidine. Urine is used for large-scale 
testing because acquisition of the sample is noninvasive and because most 
abused drugs can be detected in urine for a reasonable duration after 
ingestion. Urine testing for drugs of abuse is a two-step process. In the first 
step, screening assays are used to identify presumably positive specimens. 
Common screening tests are radioimmunoassays, enzyme immunoassays, 
fluorescence polarization immunoassay, and thin layer chromatography. Since 
they may be subject to cross-reactivity, once a possible positive sample has 
been identified by a preliminary test, a second more specific methodology, gas 
chromatography with mass spectrometry, is done to confirm the results. 
Knowledge of the pharmacology and pharmacokinetics of abused drugs 
affects selection and interpretation of test results. 
(Pharmacotherapy 1997; 17(3):497-5 10) 
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Most historians and  drug abuse experts 
propose that we are in the declining phase of a 
drug epidemic that began some 30 years ago. 
Still, substance abuse remains a major national 
public health problem. Evidence continually 
mounts demonstrating its link to crime, neglect 
of children, domestic violence, illiteracy, and the 
acquired immunodeficiency syndrome (AIDS) .’ 
The history of substance abuse in the United 
States dates back to at least 1620 when the 
Pilgrims landed at Plymouth Rock.’ Illegal drug 
use since that time has increased here as well as 
abroad, and has reached epidemic proportions. 
In the early 1960s it was estimated that 5% of the 
population had experience with illicit drugs, and 
by 1970 this number had increased to lo%.’ In 
1988 the National Institute on Drug Abuse 
estimated that 19% of the United States 
population over age 12 years had used illicit 
drugs in the preceding year. The figure jumped 
to 44% for individuals age 18-25 years.3 
Currently, 13 million Americans use illicit drugs, 
and it is estimated that half of our youth will 
have an encounter with an illicit substance 
before high school graduation.2, 
This multifaceted problem has no simple 
answer. Recognizing and documenting substance 
abuse is extremely difficult; it is far easier to 
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Table 1. U.S. Department of Health and Human Services Testing Threshold Guidelines 
Immunoassay GC-MS 
Screening Confirma tory Urinary Detection 
Drug Class Threshold Threshold Period (days) 
Amphetamines 1000 ng/ml 1-2 
Amphetamine 500 ng/ml 
Methamphetamine" 500 ng/ml 
Cannabinoids 50 ng/ml 
1 l-nor-A9-carboxylic acid 
Cocaine 
Benzoylecgonine 
Morphine 
Codeine 
Opiates 
2-8, short-term use 
15 ng/ml 14-42, long-term use 
300 ng/ml 
150 ng/ml 
2-4, short-term use 
up to 8, long-term, high dose 
300 ng/ml 1-2 
300 ng/ml 
300 ng/ml 
Phencyclidine 25 ng/ml 25 ng/ml 2-8 
Adapted from references 10, 11, and 63. 
"The specimen must also contain amphetamine at a concentration of Z 200 nglml. 
assess its results. As examples of the far-ranging 
consequences, an  estimated 10-65% of 
individuals who are seropositive for the human 
immunodeficiency virus acquired the virus due 
to intravenous drug abuse,* and 50% of persons 
arrested for serious crimes in Washington, D.C., 
in 1992 had positive urine tests for illicit drugs.6 
Therefore, it is vital that health care providers be 
alert not only to the related signs and symptoms, 
but be familiar with laboratory tests that will help 
them differentiate problems associated with drug 
use from those due to other disease etiologies. 
Urine testing for drugs of abuse has become 
increasingly popular. In addition to its use as a 
toxicologic screen in most emergency rooms, 
many employers mandate urine testing as a 
preemployment screen, guidelines have been 
established for a drug-free federal workplace that 
include urine testing, many companies perform 
for-cause testing when drug abuse is suspected, 
and random screens have long been performed 
on members of the armed services, athletes, and 
those in drug treatment f a ~ i l i t i e s . ~  Positive 
results are interpreted as objective evidence that a 
person is using the agent. The consequences 
may include counseling, termination of 
employment, imprisonment, and other corrective 
or punitive measures. 
Features of Urine Testing 
Various body fluids can be tested for the 
presence of drugs, such as blood, saliva, hair, and 
urine.' The reason for the increased frequency of 
urine testing is primarily the fact that urine is 
easily obtainable (noninvasive) and contains 
relatively high concentrations of drugs and their 
metabolites. ' 
Urine has several dikadvantages as the test 
specimen including the fact that i t  can be 
adulterated, diluted, or substituted. Drug 
concentrations in urine may vary depending on 
such factors as dose, route of administration, and 
time elapsed since administration. They also are 
influenced by urine flow, pH, and metabolism. 
Urine commonly indicates the presence or 
absence of drugs, but it cannot easily be used to 
quantify levels or to determine the time or 
duration of use. Thus it is not possible to 
establish whether an individual abuses a drug 
habitually or sporadically and casually. Also, it is 
not possible to correlate the presence of an 
abused substance in the urine with any specific 
degree of central nervous impairment in the user. 
However, some laboratories, i f  specifically 
requested, can provide quantitative levels that 
may be helpful to monitor cannabinoid levels 
after prolonged use. 
Specimens testing positive are defined as 
containing drug in concentrations equal to or 
above the designated threshold. However, the 
threshold concentration (also referred to as 
cutoff) does not specify the sensitivity or 
detection limit of the assay and only designates 
whether specimens are positive or negative.' 
Cutoff concentrations are set by the Department 
of Health and Human Services (DHHS) to define 
a positive result (Table l).'o," They are within 
the detection limit of the assay to avoid 
imprecision related to technique.', l2  The cutoff 
value can be an actual or a calculated value.13 It 
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Table 2 .  Advantages and Disadvantages of Analytic Methods9 
Method Advantages Disadvantages 
Preliminary tests 
Radioimmunoassay 
Enzyme immunoassay 
Fluorescence polarization 
Thin-layer chromatography 
Confirmation tests 
Gas chromatography 
High-performance liquid 
chromatography 
Gas chromatography- 
mass spectrometry 
Nominal personnel requirements 
Objective results 
Small sample requirements 
Minimal pretreatment 
Nominal personnel requirements 
Adaptation to batch or random- 
access analyzers 
Homogeneous 
Short analysis time 
Low equipment cost 
Rapid analysis 
Simultaneous determination of 
several drugs and metabolites 
Reliable 
Sensitive analysis 
Reproducible results 
Highly sensitive analysis 
Specificity in identification 
Radioactive isotope 
Heterogeneous assay 
Labor intensive 
Reagents expensive 
Not specific for single drugs 
Limited capacity 
Skill dependent 
Labor intensive 
Sample pretreatment 
Subjective interpretation 
Nonreproducible raw data 
Labor intensive 
Limited capacity 
Need to derivatize nonvolatile substances 
Expertise required 
High maintenance 
Similar to GC 
Costly equipment 
Complex instrumentation 
High level of skill necessary to operate and interpret data 
Individual agents in a group where mass spectra are 
similar not discernable 
infers the point at which a drug is not only 
detectable, but can be differentiated precisely 
from other, possibly endogenous, substances in 
the urine.14 The specificity and sensitivity of a 
test are affected by cutoff concentrations. If the 
concentration of drug in the urine is above the 
cutoff value, the sample is regarded as positive, 
and if it is below the cutoff value, it is considered 
negative. 
The goal of drug testing is to achieve accuracy 
with no false-positive or -negative results. A 
false-positive result is most commonly due to 
cross-reactivity of the assay with other substances 
that have structural similarity with the abused 
substance. False negatives may occur when the 
concentration of the substance in the urine is 
below the accepted threshold or when the sample 
has been diluted or otherwise adulterated to 
obscure the presence of a drug. 
Types of Tests 
Screening tests generally are performed to 
identify presumably positive specimens. These 
are followed by confirmation with a different, 
more specific, analytic test (Table 2).' 
Preliminary Tests 
Immunoassay is currently the preferred 
technique for initial urine tests.7 Several immuno- 
assays are available, including radioimmunoassay 
(RIA) ,  enzyme immunoassay (EIA), and 
fluorescence polarization immunoassay (FPIA). 
Federal guidelines do not specify the assay of 
choice, but accuracy, precision, and sensitivity 
are equal, results are comparable, and differences 
in specificity are not significant for these tests.' 
One advantage of immunoassays is that many 
specimens can be processed by automated 
instrumentation, minimizing personnel 
requirements. Also, results are objective because 
of computerized reporting9 The disadvantage is 
that these tests are often specific for a class of 
drugs rather than a single drug.' The systems are 
based on antibody binding to the drug, so that 
chemically related compounds or metabolites 
commonly cross-react, causing a false-positive 
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result. Therefore, a positive immunoassay 
requires confirmation by a more specific test. 
Radioimmunoassay is based on  a simple 
equilibrium equation. An antibody to the drug is 
generated usually in an animal such as a sheep or 
pig. Blood is drawn from the animal and the 
specific antibody is extracted and purified. 
When the extract is added to a test tube of 
sample, the antibody will bind to the drug. The 
drug-containing sample is then mixed with a 
radiolabeled ligand that competitively binds to 
the antibody. Once equilibrium is reached, the 
amount of the radiolabeled ligand that is not 
bound to the antibody directly correlates with the 
amount of drug in the ~amp1e. l~ 
The enzyme multiplied immunoassay technique 
(EMIT) is the most common EIA. It is based on 
the principles of RIA but  does not  use 
radiolabeled antibodies.  I t  is based o n  
measurement of the  enzymatic activity of 
glucose-6-phosphate dehydrogenase (G6PD) 
derived from the bacterium Leuconostoc 
rnesenteroides. In the presence of a substrate such 
as glucose, this enzyme reduces the cofactor 
nicotinamide adenine dinucleotide (NAD) to 
reduced NAD (NADH). An enzyme-drug 
conjugate is prepared by combining the G6PD 
enzyme with molecules of the drug to be assayed. 
To measure the concentration of drug in a 
sample, the enzyme-drug conjugate is added to 
the the sample fluid together with antibody to 
the drug, NAD, and a substrate for the G6PD 
enzyme. The drug  o n  the enzyme-drug 
conjugate and the free drug in the sample fluid 
compete for binding sites on the drug antibody. 
If the enzyme-drug conjugate binds to the 
antibody, a steric hindrance results in a reduction 
of enzyme activity, such that the conversion of 
NAD to NADH is decreased. The greater the 
quant i ty  of drug  i n  the sample,  the fewer 
antibodies will bind to the enzyme-drug 
conjugate, resulting in greater activity of enzyme. 
Therefore, greater production of enzymatic 
product  correlates with higher drug  
concentration. Enzyme immunoassay is the most 
widely performed init ial  test because i t  is  
sensitive and specific as well as suitable for 
testing in high-volume laboratories and on a 
variety of batch or random access analyzers.'* 
The cloned enzyme donor  immunoassay 
(CEDIA) is a newer EIA that  is  based on  
principles similar to the EMIT assay. I t  uses 
recombinant DNA technology to produce enzyme 
donor units to which a molecule of the assay 
drug is bound, and acceptor units that combine 
with drug antibodies to produce an antibody- 
enzyme-drug conjugate that cannot operate as an 
active enzyme. In the presence of assayable drug 
or metabolite, the antibody binds the free drug 
instead of the enzyme donor molecule, and an 
active enzyme produces a measurable product 
that correlates with drug concentration.16 
The FPIA is based on fluorescence polarization 
and competitive binding, Antibodies to the drug 
and a tracer drug or similar chemical labeled with 
fluorescein are mixed with the specimen 
containing drug molecules that compete for 
antibody-binding sites. In specimens with low 
analyte (drug) concentration, a large amount of 
tracer binds to antibody with subsequent high 
p o 1 ar iza t io n of flu ore sc en  c e . C o nve rs e 1 y, 
specimens with high analyte concentration result 
in low polarization of fluore~cence.'~ Because of 
differences in cutoff values, comparison of results 
with other methods should be undertaken with 
caution. l3  
Thin-layer chromatography (TLC), a 
chromatographic procedure for preliminary 
testing, can be used to determine several drugs 
and their metabolites simultaneously.' The 
sample is placed on one end of a gel-covered 
plate and allowed to move u p  the plate by 
permeation. Large molecules move more slowly, 
and the sample can be separated into 
components with this method.'* In contrast to 
immunoassay systems, TLC is labor intensive 
and the results are read by the operator, 
potentially leading to bias. Operator skill is 
therefore crucial in determining the quality of 
results. In addition, the results are not stored or 
easily retainable.' However, an advantage is its 
low equipment cost. The test can be done to 
confirm positive immunoassay results, although 
this is seldom done.13 
Other newer simple screening systems, such as 
the Triage panel, use monoclonal antibodies to 
produce a color-coded reaction, similar to home 
pregnancy tests, in the presence of drugs in  
solution at threshold or greater concentrations." 
These screening systems are fast and simple but 
tend to be expensive. 
Confirmation Tests 
Although gas chromatography with a mass 
spectrometry (GC-MS) detector is the best 
available analytical method for confirmatory 
testing, GC has been used with other types of 
detectors a s  a confirmatory technique.', l8 
However, MS is the most specific technique used 
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for identification. Gas chromatography is used to 
separate vaporized analytes carried by a gas 
across a separation column where they are 
retained for varying periods of time, depending 
on their relative affinities for the column. The 
detector then identifies a spectrum or pattern 
that is specific for a particular analyte. Mass 
spectrometry provides a fragmentation pattern 
that is usually characteristic of a specific 
compound." 
Combined GC-MS is regarded as the only 
legally defensible and most reliable method of 
testing urine for drugs of abuse." The GC 
component separates analytes and MS identifies 
them, resulting in both sensitivity and specificity. 
The disadvantage is that technical skill and 
experience are necessary to operate the instrument 
and interpret the results, making the system 
labor intensive and expensive. 
High-performance liquid chromatography 
(HPLC) is also done for confirmation testing. It 
is similar to GC, but the analytes do not require 
vaporization, and the carrier is a liquid rather 
than a gas.15 Although the test is highly 
sensitive, specific confirmation requires a method 
such as MS to determine the actual component of 
each HPLC peak. In addition, HPLC is labor 
intensive and time consuming because only one 
sample can be analyzed at a time. 
Commonly Assayed Drugs of Abuse 
Alcohol, barbiturates, and benzodiazepines are 
commonly abused. Drugs that are included in 
the DHHS guidelines for testing in the workplace 
include amphetamines, cannabinoids, cocaine, 
opiates, and phencyclidine (PCP)." In some 
cases the drug itself is measured in urine testing, 
in other cases it is a metabolite. Knowledge of 
the pharmacology of these drugs is important for 
interpreting urine tests. 
Alcohol 
Despite the ubiquity and legal availability of 
alcohol (ethanol), urine testing for the agent is 
not commonly performed. Several reasons 
account for this. First, it is not one of the five 
drugs mandated for testing by the DHHS, 
although the Department of Transportation 
guidelines now require breath alcohol testing. 
Second, urine alcohol concentrations correlate 
poorly with blood concentrations. Breath and 
blood alcohol concentrations correlate more 
closely with central nervous system (CNS) effects 
and are used to determine whether an individual 
is operating a vehicle while impaired due to 
alcohol. 
After oral ingestion alcohol is metabolized, 
principally by alcohol dehydrogenase, to 
acetaldehyde and ultimately to carbon dioxide 
and water by acetaldehyde dehydrogenase. A 
small amount is also metabolized by the micro- 
soma1 enzyme system. Alcohol's pharmacokinetics 
are complicated, and it is commonly stated that its 
elimination is zero order." However, this is 
somewhat less than true because its elimination 
conforms to Michaelis-Menton pharmacokinetics, 
which means that the speed of elimination is 
concentration dependent.20 Consequently, blood 
alcohol levels over time in a specific individual are 
not as predictable as was once believed. 
Pharmacologic effects of alcohol are well known 
and range from stimulation and disinhibition at  
lower concentrations to impairment of 
coordination and speech, respiratory depression, 
and possibly death at high concentrations.2' 
Blood alcohol concentrations 0.05 g% and above 
are associated with measurable impairment in 
complex tasks requiring divided attention, such 
as driving.22 
Blood is the preferred matrix for testing alcohol 
concentrations and is usually preferred to urine. 
Breath alcohol concentrations also correlate more 
closely with blood alcohol concentrations than 
do urine concentrations. For urine testing a 
biochemical method is usually performed in 
which alcohol dehydrogenase oxidizes any 
alcohol that is present to acetaldehyde. The 
reaction producing acetaldehyde results in  
conversion of NAD to NADH. The concentration 
of NADH is measured spectrophotometrically 
and correlated to alcohol c~ncentrat ion.~~ 
It is important to recognize that a positive test 
establishes that alcohol has been ingested, but it 
does not indicate that the amount ingested was 
sufficient to cause impairment. In addition, 
unlike PCP, cannabinoids, or cocaine, alcohol is 
widely and legally available. Therefore, persons 
with positive urine alcohol tests have not  
necessarily done anything illegal. Consequently, 
determining the significance of a positive result is 
not always straightforward. 
Amphetamines 
Amphetamine consists of not only racemic 
amphetamine, dextroamphetamine, and meth- 
amphetamine, bu t  also chemically related 
compounds such as the phenethylamines 
pseudoephedrine, phentermine, ephedrine, 
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phenylpropanolamine, and phenylephrine. Many 
of the last compounds are available in a variety of 
over-the-counter products and have the potential 
to interfere with preliminary urine tests, resulting 
in false-positive results. Notably, some other 
illegal substances, such as methylenedioxy- 
amphetamine (MDA) and methylenedioxy- 
methamphetamine (MDMA, ecstasy), have the 
potential to produce positive results in some 
immunoassays used for screening for 
amphetamines. 23 
Selegiline, a monoamine oxidase inhibitor used 
to treat Parkinson's disease, is metabolized to 
both I-amphetamine and I-rnetham~hetamine.~~ 
Since the I-isomers do not produce the euphoria 
seen with the d-isomers, selegiline is not  
commonly abused, although it tests positive in 
many immunoassays. Chiral GC-MS procedures 
that can distinguish between the d- and I-isomers 
should be applied when positive amphetamine 
urine tests may be due to ~ e l e g i l i n e . ~ ~  Large 
doses of Vicks nasal inhaler can result  in  
measurable quantities of I-rnetham~hetamine.~~ 
However, only the older EMIT-d.a.u. assay is 
affected by this interaction. Even twice the 
recommended dose of Vicks inhaler causes no 
false positive by EMIT monoclonal amphetamine- 
methamphetamine or EMIT I1 amphetamine- 
methamphetamine assays. 
Racemic mixtures or d-isomers of amphetamines 
cause mood elevation, increased alertness, and 
decreased appetite, and may be prescribed to 
treat hyperactive children or narcolepsy.26 
Central nervous system effects are mediated by 
release of dopamine and norepinephrine from 
central neurons. The typical abuser combines 
amphetamines with alcohol, barbiturates,  
benzodiazepines, or opiates to minimize the 
undesirable effects of amphetamines. Tablets 
frequently are obtained from legal sources but 
diverted to the illicit market; they may be taken 
orally or crushed and injected intravenously to 
obtain the euphoric effects. Alternatively, 
amphetamines may be synthesized by illicit 
laboratories in a form that can be easily dissolved 
and injected or smoked. Common street names 
for amphetamines are uppers, pep pills, bennies, 
meth,  crank, dexies, hearts,  whites, black 
beauties, speed, crystal, and ice, a smokeable 
form of methamphetamine.'. 26 
Peak plasma concentrations are achieved very 
rapidly after intravenous administration of an 
amphetamine, and maximum concentrations 
after oral ingestion usually occur within 2 
hours.26 Half-lives of the different amphetamines 
vary, but generally range from 8-12 hours.26 
Amphetamine sulfate is metabolized in the liver 
by aromatic hydroxylation, N-dealkylation, and 
deamination, whereas methamphetamine is slowly 
metabolized to a m ~ h e t a m i n e . ~ ~  Approximately 
half the dose of either agent is excreted in urine 
~ n c h a n g e d . ~ ~ - ~ '  Urinary excretion of unchanged 
drug is pH dependent; urinary acidification to pH 
less than 5.6 yields a plpma half-life of 7-8 
hours, whereas alkalinization may increase the 
half-life to up to 33.6 hours.26, 27 
Both TLC and the immunoassays are used for 
preliminary testing for amphetamines, but TLC is 
more specific. The immunoassays vary in their 
specificity for amphetamine; RIA appears to be 
the most specific followed by FPIA and EIA.313 32 
The newer EMIT assays differ in their specificity 
for the agents. The EMIT amphetamine class 
assay contains polyclonal antibodies that cross- 
react with many drugs that have an amphetamine- 
like structure.33 The EMIT-d.a.u. monoclonal 
amphetamine-methamphetamine assay is much 
more specific for amphetamine and meth- 
amphetamine but  i t  also detects MDA and 
MDMA.34. 35 The EMIT I1 amphetamine- 
methamphetamine assay also contains mono- 
clonal antibodies and is even more specific for 
detecting only amphetamine and meth- 
am~hetarn ine .~~ The lack of specificity of many 
preliminary tests emphasizes the need to confirm 
a positive result by either GC or GC-MS.9.3740 
Barbiturates 
Barbiturates can produce CNS mood 
alterations ranging from excitation to mild 
sedation, hypnosis, and deep coma. At the lower 
end of the dosage range the agents usually 
produce relaxation and euphoria. Barbiturates 
are classified based on duration of action and 
specific clinical use.7 Common street names are 
barbs, downers, and goofballs; blues or blue 
heavens (amobarbital);  yellow jackets 
(pentobarbital);  red birds or red devils 
(secobarbital); and rainbows and red-and-blues 
(secobarbital and amobarbital) .', ' 
These drugs are absorbed to varying degrees 
after oral ingestion, with onsets of action ranging 
from 20-60 minutes.41 They are weak acids that 
are primarily in the nonionized state in the 
blood, result ing in  a high degree of lipid 
solubility. They are rapidly distributed to all 
tissues and fluids, with high concentrations in 
the brain, liver, and kidneys. Barbiturates are 
metabolized primarily by the hepatic microsomal 
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enzyme system, and metabolites are excreted in 
urine and feces.42 Approximately 25-50% of 
phenobarbital, a long-acting agent, is excreted 
unchanged in urine, whereas only negligible 
amounts of other short- and intermediate-acting 
barbiturates are excreted in the urine.33 Total 
elimination is more rapid in young than in 
elderly persons; the elimination rate in infants is 
2-5 times faster than in adults due  to the 
metabolic process.’ 
Barbiturates can be detected in for varying 
amounts of time urine depending on the half-life 
of the specific compound .’ In contrast to short- 
and intermediate-acting agents, which may test 
positive for 1-3 days, long-acting barbiturates 
may be detected for 10-14 days after a single 
dose and for several weeks after long-term use.11x23 
As with the amphetamines, TLC and immuno- 
assay are common preliminary tests for barbiturates. 
Although TLC has greater specificity, it cannot 
differentiate among agents in the same class 
(short-, intermediate-, long-acting). Immunoassay 
cannot differentiate among classes of compounds, 
although some of them are sensitive for specific 
barbiturates. Presumptive positive results are 
usually confirmed by HPLC, GC, or GC-MS. 
Benzodiazepines 
Benzodiazepines are marketed and prescribed 
worldwide as sedatives, anxiolytics, muscle 
relaxants, and anticonvulsants. Since they have 
many legitimate uses, it is sometimes difficult to 
determine whether they are being abused. The 
prescriber or dispenser can ask several questions 
to identify abuse; for example, whether the drug 
appears to be causing impairment, the dose is 
being increased without direction of the 
prescriber, and prescriptions are being refilled 
more frequently than necessary. 
The abusability of these drugs was studied in 
individuals with a history of drug abuse.43 In 
general, benzodiazepines were not rated as highly 
desirable by such individuals compared with 
other commonly abused substances. Most likely 
to be abused are those with high lipophilicity and 
rapid absorption and onset of effect, such as 
flunitrazepam and diazepam. Although 
flunitrazepam (Rohypnol) is not  currently 
marketed in the United States, it is available in 
Europe and Latin America and has developed a 
following as an illicit drug in states such as 
Florida and Texas, which are close to or border 
other 
Pharmacologic effects associated with benzo- 
diazepines include sedation, muscle relaxation, 
disinhibit ion,  ataxia,  and amnesia. Mos t  
benzodiazepines are extensively biotransformed 
by oxidation or reduction, or undergo 
conjugation with glucuronic They have 
structural similarities, and the majority can cause 
positive results of EIA urine screens due to cross- 
reactivity. The duration of detection in urine 
depends on elimination half-life, dose, and 
duration of use of the specific agent. Some 
rapidly eliminated drugs such as alprazolam may 
be detected in urine for only a few days, whereas 
more slowly eliminated ones may be detectable 
for weeks or even months after long-term use.33 
Immunoassays for urine screening are often 
calibrated with oxazepam or nordiazepam, which 
are common metabolites of many of the 
corn pound^.^^^ 45 Benzodiazepines as a class may 
be detected by immunoassay, but determining 
which specific agent is present requires GC-MS. 
Unfortunately, many laboratories do not routinely 
determine specific agents by GC-MS other than 
oxazepam, nordiazepam or diazepam. Also, since 
cutoff levels are not stipulated by the DHHS, the 
threshold for reporting a positive result varies 
depending on the 1aborato1-y.~~ 
Cannabinoids 
Cannabinoids include more than 60 C-21 
compounds found in the plant Cannabis sativa, 
commonly known as marijuana. Marijuana is 
also known as pot, Mary Jane, grass, weed, hash, 
hashish, and bhang.’ Its effects are probably the 
result of a sum of different active compounds. 
Delta-9-tetrahydrocannabinol (THC) is the major 
intoxicant and is the most extensively studied 
~annab ino id .~~  The content of THC in marijuana 
increased slightly from 2% in the 1970s to 4% in 
1988; carefully cultivated varieties such a s  
Sinsemilla may have an average THC content of 
around 7%.46 
The immediate effects of smoking cannabis are 
euphoria, altered sense of time, keener sense of 
hearing, exaggerated visual imagery, alteration in 
short- and long-term memory, impaired motor 
funct ion,  and possibly hallucinations and 
paranoia. Symptoms are usually accompanied by 
tachycardia, conjunctival reddening of the eyes, a 
feeling of hunger, and dry throat and 
Marijuana is better absorbed after smoking 
than after oral ingestion, primarily due to first- 
pass elimination in the liver. Factors that alter its 
bioavailability and onset of effect include the 
potency of THC, puff duration, volume of smoke 
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inhaled, and amount of time the smoke is held in 
the lungs. The average bioavailability of THC in 
heavy smokers is 13% higher than in  light 
smokers.’ The substance is highly lipophilic 
with a large volume of distribution (10 Ukg), 
and accumulates in many body tissues, especially 
the liver and lungs. When smoked, the peak 
plasma THC concentration is usually achieved 
within minutes. The levels are lower and more 
erratic after oral ingestion than after smoking or 
intravenous admini~tration.~’ The concentrations 
of metabolites are usually higher after oral 
ingestion. 47-49 
The initial half-life of marijuana is 3.1-4.5 
minutes, reflecting rapid distribution into tissues 
including the brain.50 After redistribution, 
marijuana has a longer elimination half-life of 
19-36 hours.46, 48, 50 After THC is transformed by 
the cytochrome P-450 system to a psychoactive 
metabolite, it  is oxidized by alcohol 
dehydrogenase to an inactive compound. It 
undergoes extensive enterohepatic c i r~u la t ion .~~  
One-third of the metabolites are eliminated by 
the kidneys and the remaining two-thirds are 
excreted in  feces. The metabolites of THC 
appear in urine for 2-8 days after short-term use 
and 14-42 days after long-term use.” 
The time after marijuana use during which a 
positive urine test may result depends on route of 
administration, potency of THC, frequency of 
use, and assay sensitivity.’ Several tests are 
effective for preliminary testing of THC and its 
metabolites, such as EMIT, RIA, and FPIA. 
Although each of these is sensitive enough for 
preliminary testing, none is specific for the 
carboxy-THC metabolite itself. Since 
chromatographic assays (TLC, HPLC, GC, GC- 
MS) specifically measure the carboxy-THC 
metabolite, they are often used for the 
confirmation test after immunoassay. The 
threshold for an immunoassay system is usually 
set at 50 ng/ml for preliminary testing and 15 
ng/ml for confirmatory analysis by GC-MS.’ 
Although any of the chromatographic methods 
may be effective, GC-MS is considered the assay 
of choice for confirmation. Immunoassay and 
GC-MS may detect urinary cannabinoid 
metabolites, but they cannot quantify the amount 
ingested or smoked. 
Anecdotal reports describe nonsmokers testing 
positive for cannabinoids after being exposed to 
passive i n h a l a t i ~ n . ~ ~ - ~ ~  It is possible that this 
could occur, but the exposure would have to be 
extensive and in  a very small closed, 
nonventilated area. The likelihood of a positive 
urine test due to passive inhalation is miniscule. 
In a report of three studies, 80 urine specimens 
from 12 subjects were collected separately over 
24 hours after passive exposure to marijuana.52 
In the first study, two nonsmokers were placed in 
a confined area with two experienced subjects 
who smoked two marijuana cigarettes containing 
2.5% THC for 1 hour. This was repeated several 
weeks later with the THC content increased to 
2.8%. In the second study, nonsmokers were 
placed on two separate occasions in a medium- 
size station wagon for 1 hour after four people 
started smoking marijuana cigarettes containing 
2.8% THC. In the final study, four smokers were 
instructed to smoke one marijuana cigarette as 
little as possible in  the presence of two 
nonsmokers.  All samples collected from 
nonsmokers were analyzed by EMIT for the 
presence of cannabinoids. Of the 80 samples, 
only 2 tested positive for THC with a value equal 
to or greater than 20 ng/ml (the threshold for 
positive urine testing is 5.0 ng/ml). Of interest, 
both of these samples were collected in the first 
void, 5 and 6 hours, respectively, after exposure. 
The results indicate that it is highly unlikely that 
a positive cannabinoid urine assay would result if 
individuals were not confined to small, 
nonventilated areas and marijuana cigarettes 
were not smoked sim~ltaneously.~~ 
Cocaine 
The abuse of cocaine increased tremendously 
in middle and late 1980s, and received much 
attention in the mass media and at federal and 
local law enforcement levels. Commonly known 
as coke, toot,  dandruff of the gods,  brain 
Tabasco, snow, and lady, it is extracted from the 
leaves of the South American shrub Evythroxylon 
57 The hydrochloride form is prepared by 
dissolving the cocaine base in hydrochloric acid, 
forming a water-soluble salt.’ Although it is 
convenient for legal medicinal purposes, cocaine 
hydrochloride is heat labile. 
Cocaine produces a more intense euphoria 
after smoking than after insufflation (snorting) or 
oral intake, so smokers convert it to the freebase 
form, an alkaloid base that is not destroyed by 
heat. Traditionally, freebase was prepared by 
extracting cocaine into an organic solvent such as 
ether, but this method lost favor since ether is 
extremely flammable.26 Freebase can be prepared 
more safely from the hydrochloride form by 
mixing it with baking soda and water.’, 26 The 
resulting alkaline solution is evaporated to form a 
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rocklike substance commonly known as crack.9 
There is no doubt that cocaine causes severe 
psychologic dependence, particularly in those 
who inject it or inhale the vapors. The drug 
produces increased alertness, depressed appetite, 
decreased perception of the need for rest, and 
intense euphoria. Acute cocaine intoxication 
leads to profound' CNS stimulation that may 
progress to seizures and cardiac arrest, 
Coca leaves are traditionally chewed or sucked, 
which results in slow absorption through the 
mucous membranes, low blood levels, and a 
relatively slow onset of action. Cocaine hydro- 
chloride is a fine powder that may be insufflated 
high into the nasal membrane mucosa, producing 
relatively quick absorption and onset of effects. 
Intravenous use leads to a quick and powerful 
but brief effect. Smoking crack results in the 
most profound effects and has become the 
method of choice for many users. The large 
surface area of the lungs is ideal for absorption, 
and circulation of blood between the lungs and 
brain is rapid,  producing effects almost 
immediately.26 
Cocaine is metabolized by ester hydrolysis and 
N-demethylation in the liver and serum.5s, 59 It is 
converted in the blood to benzoylecgonine at 
alkaline and neutral  pH by nonenzymatic 
hydrolysis, and to ecgonine methyl ester by 
pseudocholinesterase. Both metabolites are 
excreted in  ur ine,  and  the quantity and 
proportion of each do not differ with route of 
adminis t ra t i~n .~~.  60, Cocaine itself is renally 
excreted to an  appreciable degree with an  
estimated half-life of about 1 hour. The 
benzoylecgonine and ecgonine methyl ester 
metabolites have plasma half-lives of 7.5 and 3.6 
hours, respectively; they can be detected for up 
to 3 days after occasional use, and up to 8 days 
after repeated high doses.62. 63 
Immunoassays are favored for preliminary 
testing of urine for cocaine and do not require 
sample preparation or stabilization.62, 64-66 
Immunoassays target benzoylecgonine and have 
little cross-reactivity with the remaining 
metabolites, except RIA, which cross-reacts with 
cocaine? Immunoassays can detect benzoylecgonine 
at  a concentration of 300 ng/ml or less. 
Chromatographic techniques can also be used to 
detect cocaine or its metabolites in urine, but 
sample preparation is somewhat complicated. 
Gas chromatography-MS has the highest 
sensitivity and specificity in detecting cocaine 
and benzoylecgonine and is used to confirm 
preliminary tests.67 
Opiates 
Opium is derived from the Papaver somniferurn 
plant.68 During harvest, the seed pod produces a 
resinlike material from which morphine is 
extracted and heroin is derived. Raw opium 
contains about 10% morphine by weight. Heroin 
is synthesized by diacetylating morphine.68 It is 
2-3 times more potent than morphine and, due 
to the added acetyl groups, has better penetration 
across the blood-brain barrier. Street names for 
heroin include skag, dope, shill, horse, H, white 
stuff, and Lady Jane.' Although chemists have 
developed several synthetic compounds that 
produce the same narcotic effects as morphine, 
an agent that has the same analgesic effects 
without causing physical dependence has yet to 
be synthesized. 
Opiates act by binding and activating specific 
receptors in the brain, mimicking the activity of 
enkephalins and endorphins. These naturally 
occurring peptides have potent analgesic effects 
and reside in the neurons that innervate the 
midbrain gray area involved in pain perception. 
The major indication for the narcotic analgesics 
is pain control. Pain is generally relieved after 
appropriate doses, but other effects also occur, 
including euphoria,  decreased number of 
peristaltic contractions in the gastrointestinal 
tract ,  and an antitussive effect. Tolerance 
develops to the analgesic as well as the euphoric 
effects, and consequently it becomes necessary to 
increase the dose to produce or maintain the 
same effect.6s 
Due to the increase in purity of available 
heroin supplies on the street and the fear of 
contracting AIDS, many heroin users smoke 
heroin.  Even so,  since heroin is partially 
destroyed by pyrrolysis, the intravenous route is 
st i l l  preferred by many. Intravenous 
administration results in immediate high drug 
concentrations in plasma and rapid distribution 
into tissue.69 Heroin bioavailability is 
compromised when it is taken orally due to 
significant first-pass biotransformation. The 
plasma half-life is about 3 minutes due to its 
rapid conversion to morphine by hydrolysis. 70 
Morphine has oral bioavailability of 
approximately 30% due to significant first-pass 
hepatic metabolism.71% 72 In contrast, intramuscular 
administration results in  nearly complete 
b i o a va i 1 ability. Morphine undergo e s rapid 
distribution into the tissues; the volume of 
distribution varies between 1.0 and 6.2 Ykg.9 
The maximum plasma concentration is reached 
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7-20 minutes after intramuscular administration 
compared with 15-60 minutes  after oral 
ingestion.’ 
Codeine undergoes fairly rapid absorption after 
oral  adminis t ra t ion,  with peak plasma 
concentrations occurring in about 1 hour. The 
majority of i ts  analgesic effect is due  to 
conversion to morphine; 10% of a codeine dose is 
transformed to morphine and the remaining 90% 
undergoes metabolism to norcodeine. The 
glucuronide conjugates of codeine, norcodeine, 
and morphine appear in urine.’ 
Opiate agonists are metabolized mainly in the 
endoplasmic reticulum in hepatocytes by 
microsomal pathways, but  also in  the CNS, 
kidneys, lungs, and placenta. In addition to 
hydrolysis, oxidation, and N-dealkylation, opiate 
agonists undergo conjugation with glucuronic 
acid. The drugs are excreted principally in urine 
in the unchanged form and as metabolites; small 
amounts are excreted in feces.73 
Immunoassays for preliminary testing have 
adequate sensitivity but  do not distinguish 
morphine from other opiates.74- 75 They can 
detect both free and  conjugated forms of 
morphine and codeine, as well as dihydro- 
codeine, hydrocodone, hydromorphone, and 
oxycodone.’ Because they cannot distinguish 
among these compounds, confirmation must be 
performed with a more specific method.  
Chromatographic procedures appear best ,  
a l though TLC is occasionally done. Since 
codeine is metabolized to morphine, a procedure 
that can simultaneously detect and differentiate 
the two is necessary. Although HPLC, GC, and 
GC-MS are capable of this, GC-MS is preferred 
because it identifies the agent unequi~ocally.~ 
Phencyclidine 
Phencyclidine is among the five drugs required 
by the DHHS to be tested in the workplace, but it 
is  not  consistently abused throughout this 
country Its abuse appears to occur in pockets, 
primarily in selected urban areas.76 
The agent was initially synthesized in  the 
1950s as an  anesthetic,  bu t  i t  was quickly 
removed from the market due to unpredictable 
behavioral reactions that  occurred dur ing  
recovery from anesthesia. It is usually abused 
due to its euphoric and hallucinogenic effects. 
However, these effects can be quite erratic, with 
violent or bizarre behavior occurring in up to 
35% of patients who come to hospital emergency 
departments after using PCP The sensorium in 
these patients can vary from alert and oriented to 
Physical manifestations of PCP use 
are also not consistent. Tachycardia, hypertension, 
nystagmus, diaphoresis, seizures, skeletal muscle 
rigidity, and dystonias have been seen but are not 
universally present. Possible disturbing results of 
the combination of psychotic or violent behavior 
and anesthetic actions are severe injuries such as 
broken limbs, and severe younds self-inflicted by 
people who are feeling “‘no pain” and are too 
violent and agitated for medical staff to treat.77 
The drug exerts its pharmacologic effects by 
binding to a site within the N-methyl-D-aspartic 
acid (NMDA) subtype of glutamate receptors. 
Binding of PCP results in blockade of the NMDA 
calcium channel.” The drug is highly lipophilic 
and can be administered by oral and intravenous 
routes, as well as by smoking. A fo,rmerly 
popular route was smoking after spreading PCP 
on parsley or marijuana. 
The majority of PCP is hydroxylated and then 
glucuronidated; the metabolites are excreted 
renally. Up to 15% is eliminated unchanged in 
urine.79 The elimination half-life is usually about 
3 days, but urinary acidification can increase the 
speed of elimination and decrease the half-life to 
1 day.23 Usually PCP can be detected in urine for 
about 1 week, but this may increase to 2-4 weeks 
in long-term users. Few substances cross-react 
with PCP in immunoassays, although there is 
one anecdotal  report  that  large doses of 
thioridazine can cross-react.80 The presence of 
either thioridazine or PCP can be confirmed by 
GC-MS. 
Alteration of the Urine Sample 
The drug-abusing population has devised 
many ways to prevent detection of illicit drugs in 
urine. These range from ingestion of legal 
substances known to cross-react with the assays 
to in vitro adulteration by adding substances that 
interfere with the enzymatic methodology of the 
assay. Other methods are substituting a sample 
from a drug-free individual and diluting the urine 
by ingesting diuretics.”, 82 
In Vivo Cross-Reactants 
Several over-the-counter agents and foods 
cross-react with assays causing false-positive 
results for intoxicating drugs. Common cold and 
allergy preparations may interfere with various 
urine assays for  amphetamine^.'^ For example, 
diphenhydramine can cause a false positive for 
methadone, and phenylpropanolamine may test 
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positive for am~he tamine .~~  Treating urine with 
a reagent designed to eliminate these substances 
may overcome this problem, yet some 
immunoassays will still test positive. Preliminary 
assays should be followed by confirmation tests 
specific enough to alleviate all false positives. 
Poppy seeds have long been known to cause 
potentially false-positive results for opiates. 
Poppy seeds ingested in pastries, rolls, or bagels 
contain both morphine and codeine, both of 
which are excreted in ~ r i n e . ’ ~ , ’ ~ , ~ ~  This situation 
has led to the “poppy seed defense” and creates a 
dilemma for those involved in urine drug testing 
for opiatess3 Since the opiate most commonly 
abused today is heroin, it was suggested that 
urine be analyzed for a metabolite that is present 
after heroin use but  not  after poppy seed 
ingestion, to identify samples that are positive 
due to abuse. 
The presence of 6-monoacetylmorphine (6- 
MAM) is unequivocal evidence of heroin use 
because i t  is not a product of morphine or 
codeine metabolism. Thus, samples that are 
positive for opiates (codeine or morphine) by 
preliminary tests should be confirmed by a 
second procedure such as GC-MS to detect the 
me tab~ l i t e .~~  Unfortunately, 6-MAM is detectable 
in urine for only up to 8 hours after heroin 
administration, and no method is currently able 
to differentiate or distinguish morphine or 
codeine ingestion from poppy seed ingestion.23, 83 
In the early 1980s Health Inca Tea (HIT) was 
imported into the United States from South 
America. I t  was purported to cause false 
positives when testing urine for cocaine,12. 85 
probably due to the fact that it contains material 
from the plant Erythroxylon novogranatense, var 
t w i l l m e .  The average amount of cocaine in 1-g 
HIT bags reportedly is 4.8 mg. If consumers 
drink the recommended 2 cups/day (range 1-4 
cups) less cocaine is ingested than after a single 
intranasal dose.86 However, GC-MS detects 
benzoylecgonine in the urine of consumers of 
HIT. With this in mind, it is safe to conclude 
that normal patterns of consumption do not 
constitute abuse, but those overseeing urine- 
testing programs should be advised of the 
content of HIT.85,86 In 1986 the U.S. Drug 
Enforcement Agency banned the sale of this 
product in the United States, although it is 
reportedly available elsewhere. 12, 857 86 
It is widely believed that certain substances can 
be ingested that will result in a negative urine 
test even when drugs have been taken, for 
example, vitamin C, vinegar, and the herb golden 
seal (capsules or tea). There is currently no 
scientific evidence that any of these methods is 
an effective way to escape detection of drug use.82 
In Vitro Adulteration 
Attempts by illicit drug users to falsify urine 
test results resulted in the need to test samples 
for pH, specific gravity, osmolarity, temperature, 
and appearance to screen for samples that are not 
authentic. In vitro manipulation of a urine 
specimen is attractive because those subject to 
drug screens usually have minimal to no advance 
notice and little opportunity to do in  vivo 
manipulation. The most common adulterants 
reported in the literature are household vinegar, 
table salt, liquid laundry bleach, concentrated 
lemon juice, caustic household cleansers, golden 
seal tea, liquid hand soap, and Visine (tetra- 
hydrozoline hydrochloride) eye drops.”, 82, 87 
In 1988, 222 EIA-positive specimens 
confirmed by GC-MS were evaluated to 
determine if these additives invalidate enzyme 
immunoassay results and if the adulterant could 
be identified at several different  concentration^.^^ 
The authors concluded that the adulterants 
interfered differently with each of the assays. In 
vitro addition of all except lemon juice was 
capable of producing false-negative results when 
added to urine before testing. The authors 
postulated that the interference was most likely 
due  to reactions of both the drugs and 
metabolites with the adulterants. 
A concentration-dependent effect was seen 
when either liquid Drano or liquid chlorine 
bleach was mixed with amphetamine-positive 
samples8’ Sodium chloride concentrations of 75 
g/L urine produced false-negative results with 
amphetamine concentrations up to 1.42 mg/L. 
Urine samples containing 0.52 mg/L of 
amphetamine tested falsely negative when Drano 
or bleach was added at a concentration of 12 
ml/L of urine.  When the Drano or bleach 
concentration was increased to 23 mVL of urine, 
amphetamine concentrations of 1 .80 mg/L 
became negative. Samples with barbiturate 
concentrations of less than 1.45 mg/L were 
adulterated by three additives. Sodium chloride 
75 g/L, liquid hand soap, Drano, and bleach 125 
ml/L produced false-negative barbiturate test 
results. The assay for THC was the most 
sensitive to manipulation. All of the additives 
with the exception of lemon juice had an effect 
on the positive THC samples. Golden seal tea 
and vinegar produced a concentration-dependent 
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interference, whereas sodium chloride 25 g/L, 
Visine 125 ml/L, Drano, and bleach 12 ml/L 
interfered a t  all THC concentrations studied. 
Samples containing cocaine were assayed for 
the benzoylecgonine metabolite. Drano, bleach, 
and sodium chloride interfered with the assay in 
a concentration-dependent fashion. Urine 
samples with benzoylecgonine concentrations up 
to 1.18 mg/L were altered by Drano or bleach 
concentrations of 42 mVL. If the concentration 
of Drano was increased to 125 ml/L, samples 
with benzoylecgonine concentrations up to 1.82 
mg/L were altered. Two additives interfered with 
the assay for opiates. Sodium chloride interfered 
with urine opiate concentrations of less than 0.78 
mg/L, and Drano or bleach 125 mUL interfered 
with samples with up to 2.7 mg/L.87 
Detecting Adulteration 
Attempts to adulterate urine samples can be 
detected in many instances. Guidelines for the 
federal civilian employee drug program mandate 
that those being tested should not have access to 
water or chemicals that  could be used for 
adulteration at  the collection site. Bluing can be 
added to toilet water to help identify attempts to 
dilute the specimen. In addition, excess or bulky 
clothing should be removed and handbags or 
briefcases should be isolated. The specimen 
should be tested for temperature within 4 
minutes of collection (temperature should fall 
between 32.5 and 37.7"C). The appearance of 
the sample should also be noted. Foaming or 
turbidity might indicate the addition of a 
detergent or other adulterant. Unusual smells 
should be noted, such as a perfume or a strong 
ammonia odor (unusual in a fresh urine sample). 
In the laboratory, pH and specific gravity 
determinations should detect the addition of 
strong acid or alkaline substances, as well as 
dilution with water. Analysis of the sample for 
urine sodium or chloride would detect the 
addition of sodium chloride. When adulteration is 
suspected, the individual may be asked to provide 
another specimen under direct observation.82 
Summary 
Urine testing is a method to deter those who 
use drugs of abuse. Because substance abuse may 
alter cognitive performance and behavior, its 
repercussions are far reaching and might include 
decreased performance on the job. This in turn 
may decrease production or subject the drug user 
or others to physical danger, alter performance in 
sports, give rise to legal problems, make it 
difficult to obtain or hold a job, and decrease 
parenting ability. 
I t  is estimated that each year, occupational 
absenteeism and medical expenses related to 
drug use average approximately $60 b i l l i ~ n . ~  A 
relationship between these costs and urine drug 
screen results has been established.88, 89 
Individuals who test posiSive for marijuana and 
cocaine in preemployment screening have 
markedly higher accident rates, injury rates, and 
absenteeism than those who test negative. 
Consequently, urine drug testing can serve a 
useful purpose in certain instances. 
It  should be stressed, however, that urine tests 
reveal only that an individual has used a 
substance; they cannot establish the length of 
time and extent of impairment associated with 
drug use. In fact, drug use may occur without a 
positive result. Since a threshold concentration 
of the abused substance (or its metabolite) must 
be present in the specimen, positive test results 
depend on the amount of time between drug use 
and urine collection, as well as the time course 
over which the particular drug or metabolite is 
eliminated from the body. 
It is usually an administrative decision to 
perform urine drug testing as a preemployment 
screen, in athletes, in the emergency room, or as 
a condition of employment or parole. Federal 
regulations established that federal workplaces 
retain a medical review officer who is a licensed 
physician, has knowledge of substance abuse 
disorders, and is trained to interpret drug test 
results. In other places, however, the job of 
interpreting results may fall to a clinician who 
has little training in this area. 
Health care providers must be cautions in 
interpreting results because of intrinsic problems 
in sensitivity, specificity, accuracy, reliability, and 
validity of the available tests. Understanding 
these limitations as well as the pharmacology and 
pharmacokinetics of drugs is important for 
identifying possible abusers. Such information 
also allows the health care provider to identify 
sequelae of long-term drug use or to acquaint 
casual users with the possible repercussions of 
the practice. 
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